Figure 1
Trial Flow Chart

POPULATION
Patients under care of 15 older adult services with a diagnosis of Alzheimer’s disease

ELIGIBILITY
Donepezil for 3 months, on 10mg 6weeks, SMMSE 5-13, uncertainty re continued benefit of donepezil, community dwelling, carer available

CONSENT
Patient or Personal Legal Representative

BASELINE ASSESSMENT

RANDOMIZATION
MRC CTU

Donepezil 10mg
Memantine 20mg

Donepezil Placebo
Memantine 20mg

Donepezil 10mg
Memantine Placebo

Donepezil Placebo
Memantine Placebo

EXCLUSIONS
On memantine
Contraindication to trial drugs or concerns over compliance
Severe or unstable illness
Patient already in a trial

6 week assessment

18 week assessment

30 week assessment

52 week assessment

Follow up 6 monthly for subsequent 3 years

Patients under care of 15 older adult services with a diagnosis of Alzheimer’s disease

Donepezil for 3 months, on 10mg 6weeks, SMMSE 5-13, uncertainty re continued benefit of donepezil, community dwelling, carer available

Patient or Personal Legal Representative

MRC CTU

Donepezil 10mg
Memantine 20mg

Donepezil Placebo
Memantine 20mg

Donepezil 10mg
Memantine Placebo

Donepezil Placebo
Memantine Placebo

On memantine
Contraindication to trial drugs or concerns over compliance
Severe or unstable illness
Patient already in a trial

6 week assessment

18 week assessment

30 week assessment

52 week assessment

Follow up 6 monthly for subsequent 3 years